nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—OPRM1—nicotine dependence	0.981	1	CbGaD
Alvimopan—Anileridine—OPRM1—nicotine dependence	0.0051	1	CrCbGaD
Alvimopan—Urinary retention—Varenicline—nicotine dependence	0.00123	0.127	CcSEcCtD
Alvimopan—Hypokalaemia—Varenicline—nicotine dependence	0.00117	0.121	CcSEcCtD
Alvimopan—Urinary tract disorder—Varenicline—nicotine dependence	0.000881	0.0909	CcSEcCtD
Alvimopan—Connective tissue disorder—Varenicline—nicotine dependence	0.000877	0.0905	CcSEcCtD
Alvimopan—Urethral disorder—Varenicline—nicotine dependence	0.000875	0.0903	CcSEcCtD
Alvimopan—Malnutrition—Varenicline—nicotine dependence	0.000777	0.0801	CcSEcCtD
Alvimopan—Flatulence—Varenicline—nicotine dependence	0.000766	0.079	CcSEcCtD
Alvimopan—Back pain—Varenicline—nicotine dependence	0.000752	0.0775	CcSEcCtD
Alvimopan—Anaemia—Varenicline—nicotine dependence	0.000718	0.0741	CcSEcCtD
Alvimopan—Dyspepsia—Varenicline—nicotine dependence	0.000558	0.0576	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000547	0.0565	CcSEcCtD
Alvimopan—Constipation—Varenicline—nicotine dependence	0.000542	0.0559	CcSEcCtD
Alvimopan—OPRD1—Peptide GPCRs—OPRM1—nicotine dependence	0.000247	0.0576	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000232	0.0542	CbGpPWpGaD
Alvimopan—OPRK1—Peptide GPCRs—OPRM1—nicotine dependence	0.000216	0.0505	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000204	0.0475	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000172	0.0402	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000141	0.0328	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000123	0.0288	CbGpPWpGaD
Alvimopan—OPRD1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.000116	0.0271	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000104	0.0243	CbGpPWpGaD
Alvimopan—OPRK1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.000102	0.0237	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—OPRM1—nicotine dependence	9.79e-05	0.0228	CbGpPWpGaD
Alvimopan—OPRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	9.09e-05	0.0212	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—OPRM1—nicotine dependence	8.59e-05	0.02	CbGpPWpGaD
Alvimopan—OPRK1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	7.97e-05	0.0186	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	7.95e-05	0.0185	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	7.79e-05	0.0182	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—TAS2R16—nicotine dependence	7.22e-05	0.0168	CbGpPWpGaD
Alvimopan—OPRD1—G alpha (i) signalling events—DRD2—nicotine dependence	7.08e-05	0.0165	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—TAS2R16—nicotine dependence	6.97e-05	0.0163	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	6.83e-05	0.0159	CbGpPWpGaD
Alvimopan—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	6.57e-05	0.0153	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—TAS2R16—nicotine dependence	6.33e-05	0.0148	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—FGD1—nicotine dependence	6.24e-05	0.0145	CbGpPWpGaD
Alvimopan—OPRK1—G alpha (i) signalling events—DRD2—nicotine dependence	6.21e-05	0.0145	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—OPRM1—nicotine dependence	5.93e-05	0.0138	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	5.89e-05	0.0137	CbGpPWpGaD
Alvimopan—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	5.76e-05	0.0134	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—FGD1—nicotine dependence	5.67e-05	0.0132	CbGpPWpGaD
Alvimopan—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	5.63e-05	0.0131	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—FGD1—nicotine dependence	5.47e-05	0.0128	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—TAS2R16—nicotine dependence	5.35e-05	0.0125	CbGpPWpGaD
Alvimopan—OPRM1—G alpha (i) signalling events—DRD2—nicotine dependence	5.25e-05	0.0122	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—OPRM1—nicotine dependence	5.2e-05	0.0121	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—FGD1—nicotine dependence	4.97e-05	0.0116	CbGpPWpGaD
Alvimopan—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	4.94e-05	0.0115	CbGpPWpGaD
Alvimopan—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	4.87e-05	0.0114	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—FGD1—nicotine dependence	4.62e-05	0.0108	CbGpPWpGaD
Alvimopan—OPRD1—GPCR ligand binding—DRD2—nicotine dependence	4.29e-05	0.01	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—TAS2R16—nicotine dependence	4.26e-05	0.00994	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—FGD1—nicotine dependence	4.2e-05	0.00979	CbGpPWpGaD
Alvimopan—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	4.17e-05	0.00973	CbGpPWpGaD
Alvimopan—OPRK1—GPCR ligand binding—DRD2—nicotine dependence	3.76e-05	0.00877	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—TAS2R16—nicotine dependence	3.74e-05	0.00872	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—OPRM1—nicotine dependence	3.35e-05	0.00781	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—FGD1—nicotine dependence	3.35e-05	0.0078	CbGpPWpGaD
Alvimopan—OPRM1—GPCR ligand binding—DRD2—nicotine dependence	3.18e-05	0.00741	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—TAS2R16—nicotine dependence	3.16e-05	0.00737	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—OPRM1—nicotine dependence	3.04e-05	0.0071	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—AKR1B10—nicotine dependence	2.96e-05	0.00689	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—OPRM1—nicotine dependence	2.94e-05	0.00685	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—FGD1—nicotine dependence	2.93e-05	0.00684	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—OPRM1—nicotine dependence	2.67e-05	0.00622	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—AKR1B10—nicotine dependence	2.59e-05	0.00604	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—FGD1—nicotine dependence	2.48e-05	0.00578	CbGpPWpGaD
Alvimopan—OPRD1—GPCR downstream signaling—DRD2—nicotine dependence	2.42e-05	0.00565	CbGpPWpGaD
Alvimopan—OPRD1—Signaling by GPCR—DRD2—nicotine dependence	2.2e-05	0.00513	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—AKR1B10—nicotine dependence	2.19e-05	0.00511	CbGpPWpGaD
Alvimopan—OPRK1—GPCR downstream signaling—DRD2—nicotine dependence	2.12e-05	0.00495	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—WASF2—nicotine dependence	2.08e-05	0.00486	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—WASF1—nicotine dependence	2e-05	0.00466	CbGpPWpGaD
Alvimopan—OPRK1—Signaling by GPCR—DRD2—nicotine dependence	1.93e-05	0.0045	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—WASF2—nicotine dependence	1.83e-05	0.00426	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—OPRM1—nicotine dependence	1.8e-05	0.00419	CbGpPWpGaD
Alvimopan—OPRM1—GPCR downstream signaling—DRD2—nicotine dependence	1.8e-05	0.00419	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—WASF1—nicotine dependence	1.75e-05	0.00408	CbGpPWpGaD
Alvimopan—OPRM1—Signaling by GPCR—DRD2—nicotine dependence	1.63e-05	0.0038	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—OPRM1—nicotine dependence	1.58e-05	0.00368	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—WASF2—nicotine dependence	1.54e-05	0.0036	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—WASF1—nicotine dependence	1.48e-05	0.00345	CbGpPWpGaD
Alvimopan—OPRD1—Signaling Pathways—DRD2—nicotine dependence	1.3e-05	0.00303	CbGpPWpGaD
Alvimopan—OPRK1—Signaling Pathways—DRD2—nicotine dependence	1.14e-05	0.00266	CbGpPWpGaD
Alvimopan—OPRM1—Signaling Pathways—DRD2—nicotine dependence	9.63e-06	0.00225	CbGpPWpGaD
